Reported Earlier, Insulet's Omnipod 5 System Proves Effective in Type 2 Diabetes Management
Reported Earlier, Insulet's Omnipod 5 System Proves Effective in Type 2 Diabetes Management
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today shared positive results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) type 2 diabetes pivotal trial at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida. This landmark study evaluated the impact of AID in a diverse group of people with type 2 diabetes who require insulin.
全球領先的無管胰島素泵技術公司銀休特（Insulet or the Company）的Omnipod品牌產品，今天在美國糖尿病協會（ADA）第84屆科學會議上公佈了其Omnipod 5自動胰島素輸送系統（Omnipod 5）的2型糖尿病關鍵試驗的積極結果。這項具有里程碑意義的研究評估了對需要胰島素的不同人群的AID的影響。
The SECURE-T2D pivotal trial results showed glycemic improvements with the use of Omnipod 5 compared with prior treatment of insulin injections or pump therapy in adults with type 2 diabetes. The study results showed significant reductions in HbA1c, time in hyperglycemia, and total daily insulin dose, and a large improvement in time in range (TIR), without increasing time in hypoglycemia. The study also demonstrated a clinically meaningful improvement in diabetes distress.
SECURE-T2D關鍵試驗結果顯示，與2型糖尿病成人之前治療的胰島素注射或泵療法相比，使用Omnipod 5能改善血糖控制。該研究結果表明，在不增加低血糖時間的情況下，HbA1c、高血糖時間和每日總胰島素劑量均有顯著降低，範圍內時間（TIR）顯著提高，該研究還證明了糖尿病困擾程度有臨床上顯著的改善。
譯文內容由第三人軟體翻譯。